Boron neutron capture therapy for HER2+ breast cancers: a feasability study evaluating BNCT for potential role in breast conservation therapies

Update Item Information
Publication Type dissertation
School or College College of Engineering
Department Civil & Environmental Engineering
Author Jenkins, Peter Anthony
Title Boron neutron capture therapy for HER2+ breast cancers: a feasability study evaluating BNCT for potential role in breast conservation therapies
Date 2012-12
Description A novel Boron Neutron Capture Therapy (BNCT) regimen for the treatment of HER2+ breast cancers has been proposed as an alternative to whole breast irradiation for breast conservation therapy patients. The proposed therapy regimen is based on the assumed production of boron delivery agents that would be synthesized from compounds of Trastuzumab (Herceptin ®) and oligomeric phosphate diesters (OPDs). The combination of the anti‐HER2 monoclonal antibody and the high boron loading capability of OPDs has led to the assumption that boron could be delivered to the HER2+ cancer cells at Tumor to Healthy Tissue ratios (T:H) of up to 35:1 and boron concentrations above 50 μg/g. This significantly increased boron delivery efficiency has opened new BNCT possibilities. This proof of concept study examined treatment parameters derived as the results in previous efforts in the context of patient‐specific geometry and compared calculated dose results to those observed during actual patient therapy. These results were based on dose calculations performed with a set of calculated Kerma coefficients derived from tissues specific to the regions of interest for breast cancer. A comparison was made of the dose to the tumor region, the patient's skin, and the peripheral organs. The results of this study demonstrated that, given the performance of the proposed boron delivery agent, the BNCT treatment regimen is feasible. The feasibility is based on the findings that the equivalent dose could be delivered to the treatment volume with less dose to the skin and peripheral organs. This is anticipated to improve the treatment outcomes by maintaining local control of tumor cells while reducing dose to healthy tissues.
Type Text
Publisher University of Utah
Subject BNCT; Breast Cancer; Kerma
Dissertation Name Doctor of Philosophy in Nuclear Engineering
Language eng
Rights Management Copyright © Peter Anthony Jenkins 2012
Format Medium application/pdf
Format Extent 1,783,470 bytes
Identifier etd3/id/2098
ARK ark:/87278/s6t72z89
Setname ir_etd
ID 195783
Reference URL https://collections.lib.utah.edu/ark:/87278/s6t72z89